<DOC>
	<DOC>NCT00150449</DOC>
	<brief_summary>Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.</brief_summary>
	<brief_title>Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Must have completed the doubleblind portion of the preceding trial Completed any protocol specified withdrawal phase and followup visits. Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>